|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MRPS9 |
Gene summary for MRPS9 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MRPS9 | Gene ID | 64965 |
| Gene name | mitochondrial ribosomal protein S9 | |
| Gene Alias | MRP-S9 | |
| Cytomap | 2q12.1 | |
| Gene Type | protein-coding | GO ID | GO:0006412 | UniProtAcc | P82933 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 64965 | MRPS9 | LZE2T | Human | Esophagus | ESCC | 5.17e-04 | 5.94e-01 | 0.082 |
| 64965 | MRPS9 | LZE4T | Human | Esophagus | ESCC | 5.56e-12 | 2.26e-01 | 0.0811 |
| 64965 | MRPS9 | LZE24T | Human | Esophagus | ESCC | 3.46e-11 | 2.78e-01 | 0.0596 |
| 64965 | MRPS9 | LZE6T | Human | Esophagus | ESCC | 3.67e-04 | 1.19e-01 | 0.0845 |
| 64965 | MRPS9 | P1T-E | Human | Esophagus | ESCC | 8.65e-05 | 2.98e-01 | 0.0875 |
| 64965 | MRPS9 | P2T-E | Human | Esophagus | ESCC | 1.56e-29 | 4.57e-01 | 0.1177 |
| 64965 | MRPS9 | P4T-E | Human | Esophagus | ESCC | 7.77e-26 | 7.94e-01 | 0.1323 |
| 64965 | MRPS9 | P5T-E | Human | Esophagus | ESCC | 3.08e-24 | 5.14e-01 | 0.1327 |
| 64965 | MRPS9 | P8T-E | Human | Esophagus | ESCC | 4.63e-20 | 2.32e-01 | 0.0889 |
| 64965 | MRPS9 | P9T-E | Human | Esophagus | ESCC | 3.45e-15 | 3.18e-01 | 0.1131 |
| 64965 | MRPS9 | P10T-E | Human | Esophagus | ESCC | 1.88e-33 | 5.74e-01 | 0.116 |
| 64965 | MRPS9 | P11T-E | Human | Esophagus | ESCC | 3.44e-09 | 4.02e-01 | 0.1426 |
| 64965 | MRPS9 | P12T-E | Human | Esophagus | ESCC | 2.36e-28 | 4.86e-01 | 0.1122 |
| 64965 | MRPS9 | P15T-E | Human | Esophagus | ESCC | 1.29e-27 | 6.48e-01 | 0.1149 |
| 64965 | MRPS9 | P16T-E | Human | Esophagus | ESCC | 3.07e-21 | 3.82e-01 | 0.1153 |
| 64965 | MRPS9 | P17T-E | Human | Esophagus | ESCC | 3.31e-04 | 2.58e-01 | 0.1278 |
| 64965 | MRPS9 | P20T-E | Human | Esophagus | ESCC | 2.14e-14 | 3.67e-01 | 0.1124 |
| 64965 | MRPS9 | P21T-E | Human | Esophagus | ESCC | 4.57e-48 | 9.82e-01 | 0.1617 |
| 64965 | MRPS9 | P22T-E | Human | Esophagus | ESCC | 3.89e-26 | 3.23e-01 | 0.1236 |
| 64965 | MRPS9 | P23T-E | Human | Esophagus | ESCC | 6.98e-23 | 5.72e-01 | 0.108 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00427697 | Esophagus | ESCC | DNA damage response, detection of DNA damage | 12/8552 | 13/18723 | 6.18e-04 | 3.32e-03 | 12 |
| GO:00427693 | Liver | Cirrhotic | DNA damage response, detection of DNA damage | 10/4634 | 13/18723 | 1.14e-04 | 1.14e-03 | 10 |
| GO:004276911 | Liver | HCC | DNA damage response, detection of DNA damage | 11/7958 | 13/18723 | 2.38e-03 | 1.16e-02 | 11 |
| GO:00427696 | Oral cavity | OSCC | DNA damage response, detection of DNA damage | 11/7305 | 13/18723 | 1.02e-03 | 5.29e-03 | 11 |
| GO:004276913 | Oral cavity | LP | DNA damage response, detection of DNA damage | 9/4623 | 13/18723 | 8.93e-04 | 7.64e-03 | 9 |
| GO:00427698 | Skin | cSCC | DNA damage response, detection of DNA damage | 10/4864 | 13/18723 | 1.78e-04 | 1.50e-03 | 10 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa03010211 | Esophagus | ESCC | Ribosome | 129/4205 | 167/8465 | 1.43e-13 | 3.43e-12 | 1.75e-12 | 129 |
| hsa03010310 | Esophagus | ESCC | Ribosome | 129/4205 | 167/8465 | 1.43e-13 | 3.43e-12 | 1.75e-12 | 129 |
| hsa0301022 | Liver | Cirrhotic | Ribosome | 127/2530 | 167/8465 | 2.12e-35 | 7.06e-33 | 4.35e-33 | 127 |
| hsa0301032 | Liver | Cirrhotic | Ribosome | 127/2530 | 167/8465 | 2.12e-35 | 7.06e-33 | 4.35e-33 | 127 |
| hsa0301042 | Liver | HCC | Ribosome | 128/4020 | 167/8465 | 7.32e-15 | 2.23e-13 | 1.24e-13 | 128 |
| hsa0301052 | Liver | HCC | Ribosome | 128/4020 | 167/8465 | 7.32e-15 | 2.23e-13 | 1.24e-13 | 128 |
| hsa0301030 | Oral cavity | OSCC | Ribosome | 128/3704 | 167/8465 | 2.42e-18 | 1.62e-16 | 8.25e-17 | 128 |
| hsa03010114 | Oral cavity | OSCC | Ribosome | 128/3704 | 167/8465 | 2.42e-18 | 1.62e-16 | 8.25e-17 | 128 |
| hsa03010210 | Oral cavity | LP | Ribosome | 127/2418 | 167/8465 | 1.22e-37 | 4.05e-35 | 2.61e-35 | 127 |
| hsa0301038 | Oral cavity | LP | Ribosome | 127/2418 | 167/8465 | 1.22e-37 | 4.05e-35 | 2.61e-35 | 127 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MRPS9 | SNV | Missense_Mutation | novel | c.881A>G | p.Lys294Arg | p.K294R | P82933 | protein_coding | tolerated(0.15) | benign(0.003) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MRPS9 | SNV | Missense_Mutation | novel | c.667C>T | p.Arg223Trp | p.R223W | P82933 | protein_coding | deleterious(0.01) | benign(0.427) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MRPS9 | SNV | Missense_Mutation | c.511N>G | p.Asn171Asp | p.N171D | P82933 | protein_coding | tolerated(0.64) | benign(0) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MRPS9 | SNV | Missense_Mutation | c.1174N>C | p.Thr392Pro | p.T392P | P82933 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-CM-5341-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | fluorouracil | SD | |
| MRPS9 | SNV | Missense_Mutation | c.128N>A | p.Arg43Lys | p.R43K | P82933 | protein_coding | tolerated_low_confidence(0.89) | benign(0.015) | TCGA-G4-6295-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MRPS9 | SNV | Missense_Mutation | rs765595224 | c.785A>G | p.Tyr262Cys | p.Y262C | P82933 | protein_coding | deleterious(0.03) | possibly_damaging(0.635) | TCGA-AP-A054-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD |
| MRPS9 | SNV | Missense_Mutation | rs768755208 | c.1163N>A | p.Arg388His | p.R388H | P82933 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| MRPS9 | SNV | Missense_Mutation | rs771129322 | c.965G>A | p.Arg322Gln | p.R322Q | P82933 | protein_coding | tolerated(0.24) | probably_damaging(0.971) | TCGA-AX-A2HA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MRPS9 | SNV | Missense_Mutation | novel | c.1124N>A | p.Arg375His | p.R375H | P82933 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AX-A3FT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MRPS9 | SNV | Missense_Mutation | novel | c.367N>T | p.Pro123Ser | p.P123S | P82933 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AX-A3G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |